Isocorydine (Synonyms: NSC 32979) |
Catalog No.GC38414 |
L'isocorydine est isolée de Dicranostigma leptopodum (Maxim.) Fedde (DLF). L'isocorydine associée À la doxorubicine (DOX) a un potentiel prometteur pour éradiquer le carcinome hépatocellulaire (CHC).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 475-67-2
Sample solution is provided at 25 µL, 10mM.
Isocorydine is isolated from Dicranostigma leptopodum (Maxim.) Fedde (DLF). Isocorydine combines with Doxorubicin (DOX) has a promising potential to eradicate hepatocellular carcinoma (HCC)[1].
Isocorydine (0-400 ug/ml; 48 hours) show a significant decrease in the IC50 for ICD and DOX, the CI values are 0.605, 0.644, 0.804, and 0.707 respectively for Huh-7, Hep-G2, SNU-449 and SNU-387[1]. Isocorydine (0-400 ug/ml; 48 hours) abrogates DOX-induced upregulation of mesenchymal markers and the downregulation of epithelial markers in human HCC cell lines[1]. Cell Viability Assay[1] Cell Line: Huh-7, Hep-G2 , SNU-387, SNU-449 cells
Isocorydine (intraperitoneal injection; 0.4 mg/kg; every 2 days for 2 weeks) retards the tumor growth, but the combined treatment of Doxorubicin (DOX) or ICD significantly inhibits tumor growth[1]. Animal Model: Female nude mice[1]
[1]. Pan JX, et al. Isocorydine suppresses doxorubicin-induced epithelial-mesenchymal transition via inhibition of ERK signaling pathways in hepatocellular carcinoma. Am J Cancer Res. 2018 Jan 1;8(1):154-164. eCollection 2018.
Average Rating: 5
(Based on Reviews and 14 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *